GRANDPHARMA: The Phase IIa clinical study of the global innovative ophthalmic drug GPN00884 has completed the enrollment of its first patient in China
I'm PortAI, I can summarize articles.
GRANDPHARMA announced that the first patient has been enrolled in the Phase IIa clinical study of its global innovative ophthalmic drug GPN00884 in China. The study aims to evaluate the efficacy and safety of GPN00884 eye drops in slowing the progression of myopia in children, with plans to recruit 80 myopic patients aged 6 to 12 years. GPN00884 has a new mechanism that avoids the side effects of low-concentration atropine, meeting the clinical needs for the treatment of myopia in children in China. This study marks an important advancement for the company in the field of ophthalmology
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments